Esfam Biotech
Esfam Biotech is a Melbourne-based biotech company focused on world-first molecular research into significant diseases affecting global populations. They develop small molecules with novel mechanisms of action for late-stage oncology and respiratory diseases, and are engaged in groundbreaking research targeting COVID-19, prostate cancer, and viral infections in pigs. Their mission is to bring scientific breakthroughs to market to improve global health.
Industries
Nr. of Employees
small (1-50)
Esfam Biotech
C/o Department of Clinical Pharmacology and Theraputics Austin Health, Level 5, Townsend Building, Sudley Road, Heidelberg Victoria 3084, Australia
Patents
Products
Antiviral small-molecule candidate for SARS-CoV-2 (preclinical)
A small-molecule candidate designed to block SARS-CoV-2 binding to host cells via a mechanism distinct from ACE2 interaction; demonstrated prophylactic and therapeutic activity in cell-based assays and animal models and being developed as injectable and inhalational formulations.
Small-molecule oncology candidate for advanced prostate cancer (preclinical)
A non-hormonal small-molecule candidate that has shown potent anti-cancer effects in cell and animal models against prostate cancers unresponsive to hormone blockade; progressing through preclinical evaluation toward human trials.
Veterinary antiviral candidate for PRRS (preclinical)
Small-molecule inhibitors identified that block PRRS virus binding in cell-based assays with planned progression to animal testing for a first-in-class agricultural therapeutic.
Antiviral small-molecule candidate for SARS-CoV-2 (preclinical)
A small-molecule candidate designed to block SARS-CoV-2 binding to host cells via a mechanism distinct from ACE2 interaction; demonstrated prophylactic and therapeutic activity in cell-based assays and animal models and being developed as injectable and inhalational formulations.
Small-molecule oncology candidate for advanced prostate cancer (preclinical)
A non-hormonal small-molecule candidate that has shown potent anti-cancer effects in cell and animal models against prostate cancers unresponsive to hormone blockade; progressing through preclinical evaluation toward human trials.
Veterinary antiviral candidate for PRRS (preclinical)
Small-molecule inhibitors identified that block PRRS virus binding in cell-based assays with planned progression to animal testing for a first-in-class agricultural therapeutic.
Services
End-to-end discovery and preclinical development of small‑molecule therapeutics, including target identification, in silico design, cell and animal efficacy testing, formulation development and preparation for clinical entry.
End-to-end discovery and preclinical development of small‑molecule therapeutics, including target identification, in silico design, cell and animal efficacy testing, formulation development and preparation for clinical entry.
Expertise Areas
- Small-molecule drug discovery
- Computational drug design
- Preclinical development (cell assays and animal models)
- Inhalation and injectable formulation development
Key Technologies
- In silico molecular modelling
- Cell-based antiviral and oncology assays
- Animal efficacy models
- Dry powder inhalation formulation